

# PRIOR AUTHORIZATION CRITERIA

<b>DRUG CLASS</b>	<b>PROTON PUMP INHIBITORS</b>
<b>BRAND NAME (generic)</b>	<b>ACIPHEX</b> (rabeprazole)  <b>ACIPHEX SPRINKLES</b> (rabeprazole)  <b>DEXILANT</b> (dexlansoprazole)  (esomeprazole strontium)  <b>KONVOMEK</b> (omeprazole/sodium bicarbonate)  <b>NEXIUM</b> (esomeprazole)  <b>PREVACID</b> (lansoprazole)  <b>PRILOSEC</b> (omeprazole)  <b>PROTONIX</b> (pantoprazole)  <b>ZEGERID</b> (omeprazole/sodium bicarbonate)
<b>Status: CVS Caremark® Criteria</b> <b>Type: Post Limit Prior Authorization</b>	

## POLICY

### FDA-APPROVED INDICATIONS

Indication	AcipHex (rabeprazole)	AcipHex Sprinkles (rabeprazole)	Dexilant (dexlansoprazole)	Konvomek (omeprazole/ sodium bicarbonate)	Nexium (esomeprazole)  Esomeprazole strontium	Prevacid (lansoprazole)	PriLOSEC (omeprazole)	Protonix (pantoprazole)	Zegerid (omeprazole/ sodium bicarbonate)
Short-term treatment of active duodenal ulcer	✓					✓	✓		✓

PPI Post Limit Policy UDR 04-2023.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2023 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423

Helicobacter pylori eradication to reduce the risk of ulcer recurrence*	✓				✓	✓	✓		
Maintenance of healing of duodenal ulcers						✓			
Short-term treatment of gastric ulcer				✓		✓	✓		✓
Short-term treatment of symptoms associated with GERD	✓	✓	✓		✓	✓	✓	✓	✓
Short-term treatment of erosive esophagitis / GERD	✓		✓		✓	✓	✓	✓	✓
Maintenance healing of erosive esophagitis	✓		✓		✓	✓	✓	✓	✓
Pathological hypersecretory conditions	✓				✓	✓	✓	✓	
Short-term treatment of NSAID-associated gastric ulcer						✓			
Risk reduction of NSAID-associated gastric ulcer					✓	✓			
Risk reduction of upper GI bleeding in critically ill patients				✓					✓ Suspension

\*The PPI is used in conjunction with antibiotics.

## **COVERAGE CRITERIA**

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for any of the following: A) Barrett's esophagus as confirmed by biopsy, B) Hypersecretory syndrome, such as Zollinger-Ellison, confirmed with a diagnostic test

**OR**

- The requested drug is being prescribed for any of the following: A) Endoscopically verified peptic ulcer disease, B) Frequent and severe symptoms of chronic gastroesophageal reflux disease (GERD), C) Atypical symptoms or complications of GERD

**OR**

- The patient is at high risk for gastrointestinal (GI) adverse events  
[Note: Risk factors for serious GI adverse events include, but are not limited to, the following: chronic nonsteroidal anti-inflammatory drug (NSAID) therapy, history of peptic ulcer disease and/or GI bleeding, treatment with oral corticosteroids, treatment with anticoagulants, poor general health status, or advanced age.]

## **REFERENCES**

1. Aciphex [package insert]. Wixom, MI: Woodward Pharma Services LLC; March 2022.
2. Aciphex Sprinkles [package insert]. Rockville, MD: Atyu Therapeutics, LLC/Cerecor, Inc.; December 2020.

PPI Post Limit Policy UDR 04-2023.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2023 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423

3. Dexilant [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; March 2022.
4. Esomeprazole Strontium [package insert]. Ripley, MS: Sterling Knight Pharmaceuticals LLC; April 2022.
5. Konvomep [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc.; December 2022.
6. Nexium [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2022.
7. Omeprazole Capsules [package insert]. East Windsor, NJ: Aurobindo Pharma USA, Inc.; February 2022.
8. Prevacid, Prevacid SoluTab [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; March 2022.
9. Prilosec Granules [package insert]. Zug, Switzerland: Covis Pharma; March 2022.
10. Protonix [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; March 2022.
11. Zegerid [package insert]. Bridgewater, NJ: Salix Pharmaceuticals; March 2022.
12. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed February 22, 2023.
13. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 02/22/2023).
14. Shaheen N, Falk G, Iyer P, et al. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. *Am J Gastroenterol*. 2022; 117:559-587.
15. Katz P, Dunbar K, Schnoll-Sussman F, et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. *Am J Gastroenterol*. 2022; 117:27-56.
16. Falconi M, Eriksson B, Kaltsas G, et al. Consensus guidelines update for the management of functional p-NETs (F-p-NETs) and non-functional p-NETs (NF-p-NETs). *Neuroendocrinology*. 2016; 103(2): 153–171.
17. Kavitt R, Lipowska A, Anyane-Yeboah A, et al. Diagnosis and Treatment of Peptic Ulcer Disease. *The American Journal of Medicine* (2019) 132:447–456
18. Lanza FL, Chan F, Quigley E, et al. Guidelines for Prevention of NSAID-Related Ulcer Complications. *Am J Gastroenterol* 2009; 104: 728-738.